Needham & Company analyst Serge Belanger downgraded Acer Therapeutics (NASDAQ: ACER) from Buy to Hold.The analyst commented, "FDA dealt ACER ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE